Interleukin17F (IL17F) is a regulatory cytokine for T-cell-mediated immune responses. The gene coding for IL17F (IL17F) is located on chromosome 6p, a genomic region linked to asthma and asthma-related phenotypes in multiple genome scans. IL17F is expressed in lung tissue, in bronchoalveolar lavage fluid from asthmatic subjects, and in activated CD4 þ cells. We were thus interested in testing for association between single-nucleotide polymorphisms (SNPs) and haplotypes in IL17F and asthma. To characterize polymorphisms in IL17F, we sequenced this gene in a group of African Americans and a group of European Americans. A total of 50 SNPs (30 not previously reported in a public database (dbSNP build 118)) and two insertions/deletions were detected in IL17F; five of these polymorphisms were genotyped in participants of the Nurses' Health Study. We then tested for association between SNPs and haplotypes in IL17F and physician-diagnosed asthma in subjects with (cases) and without (control subjects) physician-diagnosed asthma. None of the SNPs or haplotypes tested in IL17F were associated with asthma. The polymorphisms identified in this study may be used in future studies of association between IL17F and phenotypes related to immune responses.
Introduction
Interleukin17F (IL17F), also referred to as cytokine ML-1 or IL24, is a recently discovered member of a family of cytokines (interleukin17 (IL17)) that are involved in the regulation of T-cell responses. [1] [2] [3] Members of the IL17 family stimulate T-cell proliferation and may regulate inflammatory responses and adhesion molecule expression. 4 ,5 IL17F, a protein containing 153 amino acids, shares 40% homology with IL17; this is a much higher degree of homology than IL17 shares with other members of its family. In addition to having the same two unique invariant disulfide bonds as other members of the IL17 family (IL17, IL17B, IL17C, and IL17E), IL17F has a signal peptide with a cys-cys pair that may function as an extra disulfide bond. 1 This structural difference may be the reason IL17F does not bind to either of the known IL17 receptors and may contribute to its functional distinction from IL17. 3 Structurally, the IL17F gene (IL17F) is 7742 bp in length and contains three exons. IL17F is strongly expressed in human liver, lung, and fetal liver tissue, which is unique in comparison to the expression of IL17.
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IL17F
is also expressed in inactivated mast cells and in the following cells after activation: peripheral blood mononuclear cells, T-cell clones (Th0, Th1 and Th2 phenotypes), basophils, peripheral blood CD4 þ cells, and mast cells. [1] [2] [3] The expression of IL17F in activated Th2 cells and the association of the Th2 immune response with the development of asthma led Kawaguchi and coinvestigators to examine IL17F expression in bronchoalveolar lavage (BAL) specimens obtained from subjects with asthma. They demonstrated IL17F expression in the lavage fluid from allergen-challenged BAL sites. 2 Functional analysis of IL17F indicates that it upregulates IL6 and IL8 transcripts and protein expression in primary bronchial epithelial cells.
2 IL17 has been shown to recruit neutrophils into the airways via the release of IL8; therefore, IL17F may also play a role in recruiting neutrophils to the airway via the same mechanism.
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IL17F also significantly induces expression of intracellular adhesion molecule-1, an adhesion molecule whose expression is associated with airway inflammation and asthma, in primary bronchial epithelial cells. 2, 7 IL17F induces the expression of other cytokines that may play a role in asthma, such as transforming growth factor beta-1, transforming growth factor beta-2, monocyte chemoattractant protein, lymphotoxin-b, and IL-2 from human endothelial cells. 1 These experimental data suggest that IL17F may play a role in airway inflammation and asthma by regulating cytokines involved in Th1-and Th2-like responses.
IL17F is located on chromosome 6p, a genomic region linked to asthma and asthma-related phenotypes in multiple genome scans. [8] [9] [10] On the basis of experimental findings and studies of gene expression, IL17F is a good positional candidate gene for asthma. We sequenced IL17F to characterize polymorphisms in this gene. We then tested for association between selected singlenucleotide polymorphisms (SNPs) and asthma among participants in a large cohort study, the Nurses' Health Study (NHS).
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Results
DNA sequencing
The region sequenced was approximately 7741 bp corresponding to chromosome 6 from position 52,148,322 to 52,156,063 bp (NM_052872) in the Golden Path freeze of July 2003 (http://genome.ucsc.edu). A total of 50 SNPs were detected in the two populations sequenced. Of these 50 SNPs, 30 had not been previously reported in the public database, dbSNP build 118 (http://www.ncbi.nlm.nih.gov/SNP/). Of the 23 SNPs detected in the European Americans, 14 were unique to the European American population. In all, 27 of the 37 SNPs detected in the African Americans were unique to that population. Table 1 shows the 18 SNPs occurring with a frequency of X5% in the total population. In addition, two insertions/deletions were detected in African Americans but not in European Americans. Of all of the polymorphisms detected in IL17F, five were in coding regions (c.5667C4T (rs6931727), c.7383A4G (rs2397084), c.7469G4A (rs11465553), c.7488A4G (rs763780) and c.7419_7421delinsCT). Two of these five polymorphisms were nonsynonymous, c.7383A4G (glutamic acid to glycine (126GLU-GLY)) and c.7488A4G. SNP c.7488A4G occurred with a frequency 45% and resulted in an amino-acid change from histamine to arginine (161HIS-ARG). Figure 1 shows the linkage disequilibrium (LD) patterns (plotted using r 2 ) among SNPs occurring with a frequency X5% in the European Americans (a) and African Americans (b), respectively. There were no significant blocks of LD between the SNPs detected in IL17F in either African Americans or European Americans. In European Americans, the strongest LD was observed between SNPs located near the 3 0 UTR of IL17F (c.5363A4G (rs11465551), c.7741T4G (rs1953323) and c.8487G4A), along with one SNP located 5' to these, c.À767T4C.
Association analysis
The following SNPs were genotyped in cases and controls from the NHS for the association analysis: c.1165T4C, c.2367C4T, c.7488A4G, c.8062G4C, and c.7469G4A. Four of these SNPs were selected because they were haplotype-tagging SNPs occurring with a frequency X5%; the fifth (c.7469G4A) was selected because it was a nonsynonymous coding SNP resulting in an amino-acid change from valine to isoleucine (155VAL-ILE). The average genotype completion rate for the five SNPs was 87.3% (range 78.7-94.3%). The completion rate was reduced due to a lower completion rate for SNP c.1165T4C (78.7%). The allelic and genotypic frequencies of these five SNPs are shown in Table 2 . There was no significant deviation from Hardy-Weinberg equilibrium in the cases or controls.
There was no significant association between any of the SNPs tested and physician-diagnosed asthma (Table 2) . When the genotypes were modeled using logistic regression, there was no significant association between any of the five SNPs tested and physiciandiagnosed asthma under either a dominant or additive mode of inheritance. 
Polymorphisms in IL17F and asthma CD Ramsey et al
The proc haplotype procedure created four haplotypes, each occurring at a frequency greater than 5% in the case-control population; these four haplotypes accounted for 91% of all observed haplotypes. None of these haplotypes were significantly associated with the diagnosis of asthma (Table 3) .
Discussion
We report the genetic variation in IL17F within two ethnic groups (European Americans and African Americans) in the United States. We found a total of 50 SNPs and two insertions/deletions (indels) in this population, over half of which have not been previously reported in the public database dbSNP build 118 (http://www.ncbi.nlm.nih.gov/SNP/). We did not find an association between polymorphisms in IL17F and a physician diagnosis of asthma.
More SNPs were detected in African Americans than in European Americans, which is consistent with prior reports of genetic polymorphisms. 12 Only one of the four coding SNPs was present at a frequency 45% (c.7488A4G) in the populations sequenced, but it was only present at this frequency in the African Americans. This is consistent with prior reports showing that nonsynonymous SNPs occur at a much lower frequency than noncoding (ie silent) SNPs, given their potential functional consequences.
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Although we did not find an association between IL17F and asthma, we identified many SNPs, some of which resulted in amino-acid changes and therefore may have functional consequences. To our knowledge, no functional studies of the polymorphisms in IL17F have been reported and thus it is not known whether these polymorphisms are functional variants. These SNPs could lead to changes in the inflammatory or immune response and therefore be associated with other inflammatory or immune diseases apart from asthma.
IL17F expression has been demonstrated in the BAL fluid of asthmatics and this expression may be the result of stimulation from genes located upstream in the inflammatory pathway. As IL17F is a relatively newly discovered cytokine, its role in the inflammatory pathway has not been completely elucidated. SNPs in genes located upstream in the inflammatory pathway may alter expression of IL17F as opposed to SNPs within IL17F itself. In addition, there may be different inflammatory pathways involved in the pathogenesis of atopic vs nonatopic asthma. Kawaguchi et al 2 found that IL17F was expressed in cells from the BAL fluid of patients with asthma after allergen stimulation, but not from salinechallenged sites. Thus, IL17F may influence the pathogenesis of atopic asthma, but not nonatopic asthma. We did not have information on the atopic status of our cases and controls in order to test this hypothesis.
There are several potential limitations to our study, which may have contributed to the negative results. First, only five SNPs were tested in cases and control subjects. Therefore, we may not have genotyped a sufficient number of SNPs to detect an association between variants in IL17F and asthma. However, we genotyped SNPs that captured the most frequent haplotypes, as well as the most frequent nonsynonymous coding SNP in IL17F. Secondly, our sample size may not have been large enough to detect an association for a gene with a small effect on asthma. However, we had 82% power at an alpha ¼ 0.05 to detect a relative risk of 1.6 for heterozygotes and 2.2 for homozygotes for SNPs with a minor allele frequency of X5.5%. Therefore, we were only slightly underpowered to detect an association of this magnitude for SNP c.7488A4G (power ¼ 77%) and for the rare SNP, c.7469G4A (power ¼ 70%), as they both Polymorphisms in IL17F and asthma CD Ramsey et al had minor allele frequencies o5.5%. For SNPs c.1165T4C and c.2367C4T, we had over 99% power to detect a relative risk of the magnitude noted above. If the effect of this gene was stronger, with a relative risk of 1.7 for heterozygotes and 2.4 for homozygotes, then we had over 80% power to detect an association for all SNPs tested. Despite the adequate power to detect an association in the single SNP analysis, the lower completion rate for genotyping in two of the five SNPs used for the association analysis creates a problem in estimating haplotypes. It is difficult to predict in which direction the missing data would bias the results of the haplotype analysis, and therefore these results should be interpreted with caution. However, as there was no association between any of the SNPs used to determine haplotypes and asthma when tested individually, it is unlikely that there would have been a significant association between any of the common haplotypes and asthma in the NHS population. Finally, the outcome used for the association analysis was a self-reported physician diagnosis of asthma. However, the case definition for asthma used in the NHS is stricter than in most epidemiologic studies and the diagnosis of asthma in United States registered nurses has been validated in a subgroup of asthmatic women in a similar cohort. 14 In addition, self-reported physician-diagnosed asthma has been associated with known risk factors for asthma in previous studies in the NHS cohort, 15 and other self-reported chronic diseases, such as chronic obstructive pulmonary disease, have been previously validated in this cohort. 16 In summary, we identified variations in IL17F in a sample of European Americans and a sample of African Americans. We did not find an association between any of the SNPs selected for genotyping and asthma. The IL17F variants identified in this study may help pursue further investigations into the potential role IL17F plays in inflammation and allergy.
Methods
Study populations DNA for sequencing of IL17F was obtained from 47 healthy, unrelated individuals from the Coriell Institute, New Jersey, as part of a larger project in genomic applications where 76 genes involved in innate immunity have been resequenced (IIPGA (http://innateimmunity. net)). Of these 47 individuals, 24 were African Americans and 23 were European Americans, based on self-reported ethnicity. Cases and controls were obtained from the NHS for the association analysis. 11 A total of 511 cases and 516 controls were genotyped for the selected haplotype-tagging SNPs as described below. Cases were The haplotypes were formed from the following SNPs in the order listed: c.1165T4C (rs1266828), c.2367C4T (rs722323), c.7469G4A (rs11465553), c.7488A4G (rs763780) and c.8062G4C (rs641701). These are the haplotypes that occurred with a frequency of X5% in the Nurses' Health Study (case-control) population.
self-reported lifelong nonsmokers with a physician diagnosis of asthma. Controls were lifelong nonsmokers without a diagnosis of asthma matched on age. All the cases and controls were white females, based on selfreported ethnicity. The characteristics of women with physician-diagnosed asthma in the NHS have been described previously. 17 Self-reported health outcomes (eg chronic obstructive pulmonary disease) in the NHS have been found to be very reliable indicators of true disease. 16 Informed consent was obtained from all the NHS study participants. The study was approved by the Institutional Review Board of the Brigham and Women's Hospital.
Sequencing methods
DNA concentration and quality were assessed using Pico-Green fluorescence (Molecular Probes, Eugene, OR, USA) and agarose gel electrophoresis, respectively. DNA samples were distributed at 20 ng per well to 96-well PCR plates. The IL17F genomic regions targeted for PCR amplification and sequencing included all exons, each with a minimum of 200 bases of flanking intron, a 2.5-kb continuous region 5 0 to the first exon, and a 2.5-kb continuous region 3 0 to the final exon. Genomic sequence was obtained for IL17F from the human genome browser at the University of California, Santa Cruz (http:// genome.ucsc.edu). PCR amplicons were designed using Primer3 (http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and are available at the IIPGA website (http://innateimmunity.net).
PCR products were treated with 1 U Exonuclease I and 5 U Shrimp Alkaline Phosphatase (Exo-SAP) for 30 min at 371C, then heated to 851C for 15 min to inactivate the enzymes. Each amplicon was sequenced in forward and reverse directions using individual PCR primers in separate reactions with Big Dye version 3 (Applied Biosystems) according to the manufacturer's protocol. Sequencing products were cleaned by centrifugation through Sephadex G-50 (Amersham-Pharmacia) in Multi-Screen (Millipore) plates. Samples were separated by capillary electrophoresis in ABI 3100 sequencers using the default sequencing protocol in 50-cm capillary arrays.
The Phred and Phrap software were used for base calling and assembly of the chromatograms (http:// www.phrap.org/). Assemblies were edited and reviewed in Consed (http://www.phrap.org/), and then processed with PolyPhred to identify polymorphic sites and assign genotypes (http://droog.mbt.washington. edu/PolyPhred.html). Chromatographs were visually inspected to confirm or reject potential SNPs and genotypes for each subject. The majority of genotypes were confirmed using bidirectional sequencing.
The SNPs are named based on cDNA sequence with reference numbers relative to the A base of the IL17F ATG start codon (numbered as 1), therefore SNPs in the promoter region located 5 0 to the first intron are marked by a negative sign. Where available, reference identifiers from dbSNP build 121 (http://www.ncbi.nlm.nih.gov/ SNP/) are also indicated.
Genotyping methods SNP selection for genotyping. The major factor influencing SNP selection was to identify a small set of SNPs that 'tagged' or distinguished the common haplotypes. 18 Haplotypes were inferred using Bayesian methods implemented by PHASE software (http://www.stas.ox. ac.uk/mathgen/software.html). 19 SNPs that distinguished the most common haplotypes were identified using the BEST algorithm. 20 This method derives the minimum number of SNPs required to tag haplotypes that occur more than once in the population. Only haplotypes that were found in the European Americans at a frequency of 5% or greater were considered, as the study population for the association analysis was composed exclusively of white subjects. Rare SNPs (minor allele frequency o5%) were considered for genotyping if the SNP led to a nonconservative amino-acid change, implying potential functional significance.
Genotyping. SNPs were genotyped using a Sequenom MassARRAY MALDI-TOF mass spectrometer (Sequenom, San Diego, CA, USA) for analysis of unlabeled single-base extension mini-sequencing reactions with a semiautomated primer design program (SpectroDE-SIGNER, Sequenom). Our protocol implements the very short extension method, whereby sequencing products are extended by only one base for three of the four nucleotides and by several additional bases for the fourth nucleotide (representing one of the alleles for a given SNP), permitting clearly delineated mass separation of the two allelic variants at a given locus. 21 PCR was performed in multi-or uniplex format, followed by a ThermoSequenase sequencing reaction using an oligonucleotide bound directly adjacent to each SNP. External amplification primers and internal interrogation primers were both designed using Primer3 (http://www.genome. wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Target primer parameters were fixed to achieve maximal probability of successful multiplex reactions, based on recommendations from Wang et al. 22, 23 Primers and flanking sequencing for the five SNPs can be found at the Innate Immunity website (http://innateimmunity. net). Following primer design, compatibility of primers for multiplex reactions was assessed using NetPrimer (http://www.premierbiosoft.com/netprimer/netprimer. html). The resulting spectra are converted into genotype using a software system called the SpectroTYPER-RT from Sequenom.
Quality control of the genotyping analysis included using a negative (water) and positive (CEPH individual 1347-02) control, as well as repeating at least 10% of samples in a blinded manner. If persistent conflicts above a level of 2% were present, then all genotyping reactions were repeated for more extensive confirmation.
Statistical methods
For the SNP discovery phase of the study, the African American and European American samples were analyzed separately. Genotype frequencies at each SNP locus were tested for consistency with Hardy-Weinberg equilibrium using an exact method. 24 Pairwise LD between each pair of SNP loci was analyzed using r 2 . 25, 26 The association analysis was performed using SAS genetics v8.2 (SAS Institute Inc, Cary, NC, USA). Allele and genotype frequencies were tested for Hardy-Weinberg equilibrium among cases and control subjects. The analysis of association between each of the five individual SNPs and asthma was performed using the SAS case-control procedure as well as logistic regression, assuming both an additive and a dominant model. Allelic and genotypic associations were tested using a w 2 test with one and two degrees of freedom, respectively, as well as the Armitage test for trend. Haplotype-disease association was tested using the Proc Haplotype command in SAS genetics, both using a haplotype frequency cutoff of 5% as well as looking at all possible haplotypes. Statistical significance was defined at the 5% level.
